Apellis eye drug succeeds in one key study, but falls short in its twin

Apellis eye drug succeeds in one key study, but falls short in its twin

Source: 
BioPharma Dive
snippet: 

A closely watched experimental treatment for a leading cause of blindness slowed the death of retinal cells in a large, late-stage study, a finding that the drug's maker, Apellis Pharmaceuticals, said Thursday will support an application to the Food and Drug Administration for approval.